profit from every $100 of sales.
$0$100
Genmab
$51.74-3.95% today
+69.8% in 1 year
1-year low $23.851-year high $57.29
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $33.13 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Genmab sold, what it kept, and what it did with the cash.
Sales went from $2.09 billion in 2022 to $3.72 billion in 2025, with $963 million of profit last year.
SalesProfit
Genmab handed back 38% of the cash it generated last year.
Buybacks $430M
Free cash flow 2025$1.1B
Bought back its own shares$430M
Paid as dividends–
Cash vs. debt$1.7B vs. $5.4B
Genmab vs. similar companies
Genmab grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Genmab | 33.1× · Expensive | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Genmab's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,088 | 2,390 | 3,121 | 3,720 | |
| 2,088 | 2,357 | 2,978 | 3,482 | |
| 902 | 772 | 1,015 | 1,250 | |
| 1,057 | 870 | 1,404 | 1,336 | |
| 785 | 631 | 1,133 | 963 | |
| 1.20 | 0.96 | 1.69 | 1.54 | |
| 100.0% | 98.6% | 95.4% | 93.6% | |
| 43.2% | 32.3% | 32.5% | 33.6% | |
| 37.6% | 26.4% | 36.3% | 25.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 4,335 | 5,232 | 6,414 | 12,873 |
| Cash | 1,424 | 2,204 | 1,380 | 1,715 |
| Total debt | 86 | 114 | 144 | 5,426 |
| Total liabilities | 408 | 545 | 1,277 | 7,026 |
| 3,927 | 4,687 | 5,137 | 5,847 | |
| 660 | 659 | 646 | 627 | |
| 19.8% | 13.6% | 20.1% | 8.9% | |
| 20.0% | 13.5% | 22.1% | 16.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 563 | 1,071 | 1,126 | 1,186 | |
| 46 | 54 | 44 | 55 | |
| 517 | 1,017 | 1,082 | 1,131 | |
| Dividends paid | – | – | – | – |
| 131 | 81 | 560 | 430 | |
| 63 | 85 | 105 | 128 |
Valuation
- 33.1×
- 44.5×
- 3.91
- 5.5×
- 8.6×
- 28.2×
- 26.7×
- 3.5%
- 3.0%
- 0.0%
Profitability
- 93.6%
- 33.6%
- 25.9%
- 26.6%
- 9.1%
- 16.0%
- 20.5%
- 21.1%
- 50.8%
- 22.3%
Growth
- +21.2%
- +8.5%
- −84.8%
- –
- −1.7%
Financial health
- 2.8×
- 0.93
- 43.3%
- 20.7×
- 2.02
- 2.17
- 1.16
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 35%of 952
Top 7%of 883
Bottom 39%of 576
Top 27%of 870
Top 31%of 985
What analysts expect
- Average price target
- $39.90
- Range
- $32.00 – $48.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.15 | 0.15 | +0.0% |
| Feb 17, 2026 | 0.05 | 0.46 | −89.1% |
| Nov 6, 2025 | 0.65 | 0.48 | +35.4% |
| Aug 7, 2025 | 0.54 | 0.39 | +38.5% |
| May 8, 2025 | 0.31 | 0.23 | +34.8% |
| Feb 12, 2025 | 0.57 | 0.28 | +103.6% |
| Nov 6, 2024 | 0.29 | 0.35 | −17.1% |
| Aug 8, 2024 | 0.22 | 0.29 | −24.1% |
News
Genmab, Incyte team up to develop experimental colorectal cancer treatmentSeeking Alpha · Oct 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
73Pass
Benjamin Graham
49No pass
Philip Fisher
78Pass
Peter Lynch
46No pass
Joel Greenblatt
19No pass
Charlie Munger
67Pass
Terry Smith
71Pass
Questions about Genmab
Is Genmab a good stock to buy?
A strong, very profitable business, but the price is high. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Genmab AI analysis
What does Genmab do?
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. It is in Biotechnology, based in Copenhagen, Denmark, with 3,088 employees.
Does Genmab pay a dividend?
No. Genmab does not pay a dividend at the moment; in 2025 it returned $430 million to shareholders by buying back its own shares.
Is Genmab stock halal?
Yes. Genmab passes our halal screen: its business is permitted and its debt is 17% of its market value, under the 30% limit. How we check
How has Genmab stock done over the past year?
Up 69.8% over the past twelve months, to $51.74. It traded between $23.85 and $57.29 and is 9.7% below its high.
Who are Genmab's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Genmab's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.